[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"uremic-toxemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:uremic-toxemia":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,52,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":35,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100602469","studies-on-adsorption-international-learning-initiative-global-100602469",false,"NCT07123909","Studies on Adsorption International Learning Initiative Global","The Use of Sorption Technologies in Patients Receiving Program Hemodialysis With Inflammatory Syndrome","SAILING","Inclusion Criteria:\n\n1. Adequate dialysis defined by a KT\u002FV index ≥ 1.4\n2. No active inflammatory process or infection\n3. Age ≥ 18 years\n4. Receiving standard hemodialysis regimen three times weekly, at least 4 hours per session\n5. Participants with elevated interleukin-6 (IL-6) and\u002For C-reactive protein (CRP) levels exceeding local laboratory reference values\n\nExclusion Criteria:\n\n1. Current use of steroids or immunosuppressive therapy\n2. History of kidney transplantation\n3. Diagnosis of cancer\n4. Pregnancy","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","Use of sorption technologies in patients undergoing maintenance hemodialysis with inflammatory syndrome and clinical manifestations of uremia",[27,28,29,30,31,32,33,34],"CKD (Chronic Kidney Disease) Stage 5D","Uremia; Chronic","Uremic; Toxemia","Inflammation Chronic","Hemodialysis","Inflammation Biomarkers","Dialysis Related Complication","Anemia Associated With End Stage Renal Disease",[36,37,38],"Program dialysis","Sorption","Complications of program dialysis","RECRUITING","2025-12-03",{"date":42,"type":43},"2025-12-10","ACTUAL",{"date":45,"type":43},"2025-06-01",{"date":47,"type":21},"2026-06-30",{"name":49,"class":50},"Botkin Hospital","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":62,"conditions":63,"keywords":68,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":51},"100489935","prognostic-role-of-the-uremic-toxin-indoxyl-sulfate-on-vascular-and-cardiac-functions-during-acute-kidney-injury-100489935","NCT05659589","Prognostic Role of the Uremic Toxin Indoxyl Sulfate on Vascular and Cardiac Functions During Acute Kidney Injury","VASC-AKI","Inclusion Criteria:\n\n* Age over 18 years old.\n* Patients hospitalized in conventional hospital departments and in intensive care units of nephrology.\n* Patients with moderate to severe AKI (KDIGO 2 or 3) without dialysis.\n* AKI from functional or organic aetiology\n\nExclusion Criteria:\n\n* Patients with severe CKD (GFR\\\u003C45ml\u002Fmin\u002F1.73 m2) or with kidney transplants.\n* Patients with AKI from septic or obstructive aetiology.\n* Patients with AKI from toxic aetiology whose toxic would be also responsable of cardia toxicity.\n* Patients with sepsis or blood inflammation.\n* Patients with severe chronic cardia dysfunction.\n* Patients with arrhythmia or complete heart block.\n* Patients with peripheral artery occlusive disease.\n* Pregnancy.\n* Patients on palliative care.",{"count":60,"type":21},105,[24],"Acute kidney injury (AKI) is a frequent disease in conventional hospital departments and in intensive care units. It's associated with a high risk to develop chronic kidney disease (CKD), even after a single small AKI episode. It's also associated with an important morbi-mortality, particularly cardiovascular (CV). Some studies have already showed a link between AKI and CV risk but pathologic mechanisms implicated are still unknown. In AKI and CKD, numerous substances, called uremic toxins (UT) are accumulating in blood. In CKD, those toxins, and particularly Indoxyl sulfate (IS), are known to have cardiac and vascular deleterious consequences. However, in AKI, whether acute accumulation of UT may trigger CV complications is unknown.\n\nThe purpose of this study is that during AKI, a high UT concentration, in particular IS, would be associated with early vascular and cardiac dysfunctions that can be characterized by the persistence of an accelerated pulse wave velocity (PWV). The main objective is to evaluate the correlation between UT concentrations (especially IS) and arterial stiffness (PWV measurement) at three months of an AKI episode in conventional hospital departments and in the intensive care unit of nephrology.",[64,29,65,66,67],"Acute Kidney Injury","Vascular Dysfunction","Cardiac Dysfunction","Cardiovascular Prognosis",[64,29,69,70,71],"vascular dysfunction","cardiac dysfunction","cardiovascular prognosis","2025-05-22",{"date":74,"type":43},"2025-05-28",{"date":76,"type":43},"2022-12-13",{"date":78,"type":21},"2026-06",{"name":80,"class":50},"Centre Hospitalier Universitaire, Amiens",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":51},"100559212","functionality-of-albumin-in-the-context-of-hemodialysis-100559212","NCT06561191","Functionality of Albumin in the Context of Hemodialysis","Effects of Dialyzer Characteristics and Dialysis Mode on Functional Properties of Albumin in Patients With Chronic Hemodialysis Treatment","FACED","Inclusion Criteria:\n\n* 18 years or older at least 3 month of hemodialysis treatment (3x\u002Fweek) with constant dialysis treatment regimen\n\nExclusion Criteria:\n\n* Age ≤ 18 years\n\n  * Less than three months of regular (3x\u002Fweek) hemodialysis treatments or less than 3 treatments\u002Fweek\n  * Acute or chronic liver disease (Child stage A or higher or fulfillment of the of the Kings College criteria)\n  * Infusion of commercial human albumin (e.g. in the context of ascites drainage) in the last three months prior to study inclusion\n  * Acute or severe chronic infections\n  * Acute tumor disease",{"count":90,"type":21},50,[24],"Hemodialysis treatment enables patients with end-stage chronic kidney disease to survive. At the same time, however, this treatment also increases cardiovascular mortality, in particular due to a chronically increased level of inflammation and usually incomplete removal of uraemic toxins. Both of these are closely linked with the functional properties of albumin.\n\nThe aim of this study is to investigate the effects of various parameters of dialysis, in particular dialyzer properties and dialysis mode on the functional properties of albumin and to what extent these parameters can be used therapeutically, to improve the treatment quality of hemodialysis treatment in the long term by modifying albumin functional properties.\n\nOur own preliminary work in this field and the current state of research indicate that, for example, the use of high-flux dialyzers can contribute to a reduction of the oxidative stress level. It also appears possible that treatment mode (haemodiafiltration instead of haemodialysis) may also have an effect on the binding and detoxification efficiency of albumin and thus on the removal of uraemic toxins.\n\nPrevious results have mostly been collected in observational studies. As a proof-of-concept study, this study will further investigate the concrete therapeutic applicability in an interventional study design.",[94,95,96,29],"Albumin","Dialysis","Redox State","2024-08-17",{"date":99,"type":43},"2024-08-19",{"date":101,"type":43},"2024-08-01",{"date":103,"type":21},"2025-12",{"name":105,"class":50},"Universität Duisburg-Essen"]